Epcoritamab Phase 3 Smashes Primary Endpoint, Cuts DLBCL Progression Risk by 60%
GMAB sits 29% above its 52-week low of $20.225.
Summary
Genmab announced highly positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival, reducing the risk of disease progression and death by 60%. This follows previous positive clinical trial news for epcoritamab in a different patient population in June, reinforcing the drug's potential. These strong efficacy results significantly de-risk the drug and pave the way for regulatory submissions, targeting a major cancer market.
At the time of this announcement, GMAB was trading at $26.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4B. The 52-week trading range was $20.23 to $35.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.